Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

Thrombosis and Haemostasis

Volumn 90, Issue 3, 2003, Pages 538-548

  Look, Maxime P ^a   Van Putten, Wim ^a   Duffy, Michael ^b   Harbeck, Nadia ^c   Christensen, Ib Jarle ^d   Thomssen, Christoph ^e   Kates, Ronald ^c   Spyratos, Frédérique ^f   Fernö, Mårten ^g   Eppenberger Castori, Serenella ^h   Sweep, C G J Fred ⁱ   Ulm, Kurt ^c   Peyrat, Jean Philippe ^j   Martin, Pierre Marie ^k   Magdelenat, Henri ^l   Brünner, Nils ^m   Duggan, Catherine ^b   Lisboa, Björn W ^e   Bendah, Pär Ola ^p   Quillien, Véronique ⁿ   Daver, Alain ^o   Ricolleau, Gabriel ^p   Meijer Van Gelder, Marion ^a   Manders, Peggy ⁱ   Fiets, W Edward ^q   Blankenstein, Marinus ^q   Broët, Philippe ^l   Romain, Sylvie ^k   Daxenbichler, Günther ^r   Windbichler, Gudrun ^r   Cufer, Tanja ^s   Borstnar, Simona ^s   Kueng, Willy ^h   Beex, Louk ⁱ   Klijn, Jan ^a   O'Higgins, Nial ^b   Eppenberger, Urs ^h   Jänicke, Fritz ^e   Schmitt, Manfred ^c   Foekens, John ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Laboratoire de Biologie Tissulaire   (France)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Lab d'Oncol Moleculaire Humaine   (France)

^k AIX MARSEILLE UNIVERSITY   (France)

^l INSTITUT CURIE   (France)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ CENTRE EUGÈNE MARQUIS   (France)

^o CENTRE PAUL PAPIN   (France)

^p CENTRE RENÉ GAUDUCHEAU   (France)

^q UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^r UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^s INSTITUTE OF ONCOLOGY   (Slovenia)

more..

Author keywords

Breast cancer; PAI 1; Pooled analysis; Prognosis; uPA

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSERVATIVE TREATMENT; DATA ANALYSIS; FEMALE; FOLLOW UP; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS;

EID: 10744232822     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th02-11-0264     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319:1681-92.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15 (Part I) and 71-85 (Part II).
3. Andreasen PA,Kjøller L,Christsen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 1-22.
4. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-96.
5. Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 1999; 107: 150-9.
6. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (n = 3424). Cancer Res 2002; 62: 4617-22.
7. Jänicke F, Prechtl A, Thomssen C, et al. for the German Chemo No Study Group. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator inhibitor type I. J Natl Cancer Inst 2001; 93: 913-20.
8. Look MP, Van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
9. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
10. Olkin I. Diagnostic statistical procedures in medical meta-analyses. Stat Med 1999; 18: 2331-41.
11. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78: 1434-41.
12. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
13. Sharp S, Sterne J. sbe 16: Meta-Analysis. Stata Technican Bulletin 1997; 38: 9-14.
14. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7: 889-94.
15. Tobias A. sbe: Assessing heterogeneity in meta-analysis: The Galbraith plot. Stata Technical Bulletin 1998; 41: 15-7.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
17. Schmitt M, Thomssen C, Ulm K, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997; 76: 306-11.
18. Van't Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 31: 530-6.
19. Van De Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. NEJM; 2002 347(25): 1999-2009.